Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Cisplatin vs Paclitaxel for Triple Neg BRCA

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2015 by Dana-Farber Cancer Institute
Myriad Genetics
Information provided by (Responsible Party):
Erica Mayer, MD, MPH, Dana-Farber Cancer Institute Identifier:
First received: October 28, 2013
Last updated: February 6, 2015
Last verified: February 2015

This research study is evaluating how well triple negative breast cancer responds to preoperative treatment with Cisplatin or Paclitaxel chemotherapy, and if use of a research test Homologous Recombination Deficiency (HRD) assay can predict response to preoperative treatment.

Condition Intervention Phase
Triple Negative Breast Cancer
Drug: Cisplatin
Drug: Paclitaxel
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Randomized Phase II Study of Preoperative Cisplatin Versus Paclitaxel in Patients With Triple Negative Breast Cancer Without Germline BRCA Mutations: Evaluating the Homologous Recombination Deficiency (HRD) Biomarker

Resource links provided by NLM:

Further study details as provided by Dana-Farber Cancer Institute:

Primary Outcome Measures:
  • Correlation between HRD biomarker and pathologic response to pre-operative Cisplatin [ Time Frame: 2 Years ] [ Designated as safety issue: No ]
    Correlation between HRD biomarker and pathologic response to pre-operative Cisplatin

  • Correlation between HRD Biomarker and pathologic response to pre-operative paclitaxel. [ Time Frame: 2 Years ] [ Designated as safety issue: No ]
    Correlation between HRD Biomarker and pathologic response to pre-operative paclitaxel.

Secondary Outcome Measures:
  • Comparison between HRD score predicting response for cisplatin versus paclitaxel [ Time Frame: 2 Years ] [ Designated as safety issue: No ]
    Comparison between HRD score predicting response for cisplatin versus paclitaxel

  • Correlation between HRD biomarker and pathologic complete response to neoadjuvant cisplatin [ Time Frame: 2 Years ] [ Designated as safety issue: No ]
    Correlation between HRD biomarker and pathologic complete response to neoadjuvant cisplatin

  • Correlation between HRD Biomarker score and pathologic complete response to paclitaxel. [ Time Frame: 2 Years ] [ Designated as safety issue: No ]
    Correlation between HRD Biomarker score and pathologic complete response to paclitaxel.

  • Correlation between HRD biomarker score and clinical response to pre-operative cisplatin. [ Time Frame: 2 Years ] [ Designated as safety issue: No ]
    Correlation between HRD biomarker score and clinical response to pre-operative cisplatin.

  • Correlation between HRD biomarker score and clinical response to preoperative paclitaxel [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    Correlation between HRD biomarker score and clinical response to preoperative paclitaxel

Estimated Enrollment: 160
Study Start Date: February 2014
Estimated Study Completion Date: June 2021
Estimated Primary Completion Date: November 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Paclitaxel
Paclitaxel will be given as an IV infusion at a dose of 80mg/m2 weekly x 12 weeks (4 cycles).
Drug: Paclitaxel
80mg/m2 weekly x 12 weeks (4 cycles).
Other Name: Taxol (NSC 125973)
Experimental: Cisplatin
Cisplatin will be given by IV at 75 mg/m2 every 3 weeks, 4 cycles.
Drug: Cisplatin
75 mg/m2 IV q 3 weeks x 4 cycles
Other Name: Platinol ®-AQ

  Show Detailed Description


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Participants must meet the following criteria on screening examination to be eligible to participate in the study
  • Pathologic documentation of invasive breast cancer by biopsy (FNA alone is not adequate).
  • AJCC clinical stage I with T1 > 1.5 cm, stage II or III invasive breast cancer.
  • Participants with multicentric or bilateral disease are eligible if at least one lesion meets stage eligibility criteria for the study and no tumor is HER2-positive. In this circumstance, the investigator must determine which will represent the target lesion to be assessed for response. This should remain consistent throughout the study. The target lesion should be selected on the basis of its size (lesion with the longest diameter) and suitability for accurate repetitive measurements.
  • Tumors must be HER2 negative defined as HER2 0 or 1+ by immunohistochemistry (IHC) assays and /or lack of gene amplification by FISH defined as a ratio < 2 on invasive tumor by local review.
  • ER and PgR status by IHC must be known. Tumor must be ER and PR negative (<1% staining) by local review.
  • Participant should have negative germline testing for BRCA1/2 gene mutations. Subjects who are considered otherwise eligible for the trial will have BRCA1/2 testing performed on an expedited basis as part of screening. If a potential subject does not have insurance coverage for testing or if results from available testing options will not be ready in time for enrollment in the study, costs for this test will be covered by the study. This form may also be used for genetic testing which will be covered by the participant's insurance and may lead to more expedited testing.
  • Participants with a germline deleterious BRCA mutation or BRCA1 or BRCA2 classified as "variant, suspected deleterious" by Myriad Genetics will not be eligible for the trial. Participants without a mutation or with only a BRCA1 or BRCA2 VUS (variant of uncertain significance) as classified by Myriad Genetics will be eligible for this study.
  • Although strongly recommended, genetic testing will not be mandatory. If a patient refuses to perform genetic testing but is otherwise eligible for the study, enrollment will be allowed.
  • Breast imaging should include imaging of the ipsilateral axilla. For subjects with a clinically positive axilla, a needle aspiration, core biopsy or SLN procedure will be performed to confirm the presence of metastatic disease in the lymph nodes. For patients with a clinically negative axilla, baseline assessment of the axilla will be performed at the discretion of the treating investigator. For patients with pathologically positive axillary lymph nodes prior to preoperative therapy, a level I and II lymph node dissection at the time of definitive surgery is recommended.
  • Participants with axillary adenopathy only are not eligible for this study.
  • Patients with a prior history of contra-lateral breast cancer are eligible if they have no evidence of recurrence of their initial primary breast cancer within the last 5 years.
  • Women ≥ 18 years of age.
  • ECOG performance status ≤1 (see Appendix A).

Laboratory Evaluation

  • Absolute neutrophil count (ANC) ≥ 1,500 / mm3
  • Platelet count ≥ 100,000/ mm3
  • Bilirubin ≤ 1.5x upper limit of normal (ULN), for patients with Gilbert syndrome, direct bilirubin will be measured instead of total bilirubin ALT, AST, ALK Phos ≤2.5 x ULN
  • Creatinine ≤ 1.5 mg/dl or creatinine clearance ≥ 60 cc/min
  • Hemoglobin ≥ 9 mg/dl
  • Use of an effective means of contraception is required in subjects of childbearing potential since study agents are known to be teratogenic. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. Women of child-bearing potential and men must agree to use adequate contraception (barrier method of birth control; abstinence) prior to study entry and for the duration of study participation.
  • Ability to understand and the willingness to sign a written informed consent document
  • Individuals with a history of other malignancies are eligible if they have been disease-free for at least 5 years and are deemed by the investigator to be at low risk for recurrence of that malignancy and did not receive prior chemotherapy. Individuals with the following cancers are eligible if diagnosed and treated within the past 5 years: cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin.
  • Patient must be willing to undergo mandatory research biopsy and blood draw. Prior to biopsy procedures patients must be able to be off medications that could increase the risk of bleeding

Exclusion Criteria:

  • Any prior chemotherapy at any time.
  • Any prior treatment for the current breast cancer, including chemotherapy, hormonal therapy, radiation or experimental therapy.
  • Ipsilateral breast recurrence, unless prior treatment consisted of excision alone for DCIS or breast conserving treatment and hormonal therapy for DCIS or invasive breast cancer.
  • Ongoing use of any other investigational or study agents.
  • Peripheral neuropathy of any etiology > grade 1 (NCI CTCAE Version 4.0- Appendix B)
  • Significant hearing loss that would prevent cisplatin administration.
  • Renal dysfunction for which exposure to cisplatin would be unsafe or require cisplatin dose modification (i.e., Cre > 1.5 mg/dl or GFR < 60 cc/min).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01982448

Contact: Erica Mayer, MD 617-632-2335 EMAYER@PARTNERS.ORG

United States, Alabama
University of Alabama Not yet recruiting
Birmingham, Alabama, United States, 35294
Contact: Andres Forero, MD    205-996-9995   
United States, Indiana
Indiana University- Simon Cancer Center Recruiting
Indianapolis, Indiana, United States, 46202
Contact: Lida Mina, MD    317-948-8310   
Principal Investigator: Lida Mina, MD         
United States, Maryland
Johns Hopkins University Recruiting
Baltimore, Maryland, United States, 21287
Contact: Vered Stearns, MD    443-287-4192   
Contact: Stacie Jeter    410-614-6138   
Principal Investigator: Vered Stearns, MD         
United States, Massachusetts
Beth Israel Deaconess Medical Center Recruiting
Boston, Massachusetts, United States, 02215
Contact: Nadine Tung, MD    617-667-1962   
Principal Investigator: Nadine Tung, MD         
Dana-Farber Cancer Institute Recruiting
Boston, Massachusetts, United States, 02215
Contact: Erica Mayer, MD, MPH    617-632-2335   
Principal Investigator: Erica Mayer, MD, MPH         
South Shore Hospital Recruiting
Weymouth, Massachusetts, United States, 02190
Contact: Meredith Faggen, MD    781-624-4800   
United States, New York
Memorial Sloan Kettering Cancer Center Not yet recruiting
New York, New York, United States
Contact: Tiffany Traina, MD       trainat@MSKCC.ORG   
United States, North Carolina
University of North Carolina- Lineberger Cancer Center Recruiting
Chapel Hill, North Carolina, United States, 27599
Contact: Carey Anders, MD    919-843-7719   
Principal Investigator: Carey Anders, MD         
Duke University Not yet recruiting
Durham, North Carolina, United States, 27710
Contact: Kelly Marcom, MD    919-660-1278   
United States, Pennsylvania
Universtiy of Pittsburgh- Magee-Womens Hospital Recruiting
Pittsburgh, Pennsylvania, United States, 15213
Contact: Shannon Puhalla, MD    412-641-6500   
Contact: Brenda Steele    412-641-2261    steebx@UPMC.EDU   
United States, Tennessee
Vanderbilt-Ingram Cancer Center Recruiting
Nashville, Tennessee, United States, 37232
Contact: Vandana Abramson, MD    615-322-4967   
Contact: Julie Scott, RN    615-936-1164   
Principal Investigator: Vandana Abramson, MD         
United States, Texas
Baylor College of Medicine Recruiting
Houston, Texas, United States, 77030
Contact: Mothaffar Rimawi, MD    713-798-6278   
Contact: Kristen Otte    (713) 798-8874   
Sponsors and Collaborators
Dana-Farber Cancer Institute
Myriad Genetics
Principal Investigator: Erica Mayer, MD Dana-Farber Cancer Institute
  More Information

No publications provided

Responsible Party: Erica Mayer, MD, MPH, Principal Invesitigator, Dana-Farber Cancer Institute Identifier: NCT01982448     History of Changes
Other Study ID Numbers: 13-383
Study First Received: October 28, 2013
Last Updated: February 6, 2015
Health Authority: United States: Institutional Review Board

Keywords provided by Dana-Farber Cancer Institute:

Additional relevant MeSH terms:
Triple Negative Breast Neoplasms
Breast Neoplasms
Breast Diseases
Neoplasms by Site
Skin Diseases
Antimitotic Agents
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Radiation-Sensitizing Agents
Therapeutic Uses
Tubulin Modulators processed this record on February 27, 2015